Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada
BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to predominately single-payer health care systems such...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2015/591260 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558975285985280 |
|---|---|
| author | Sergio M Borgia Adenike Rowaiye |
| author_facet | Sergio M Borgia Adenike Rowaiye |
| author_sort | Sergio M Borgia |
| collection | DOAJ |
| description | BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to predominately single-payer health care systems such as that found in Ontario. In hepatitis C virus (HCV) genotype 1 noncirrhotic patients with a baseline viral load of <6×106 IU/mL, treatment with sofosbuvir-ledipasvir can be shortened to eight weeks without compromising ≥95% efficacy. The number of HCV-infected patients in Ontario eligible for shortened therapy, and the associated cost savings, are unknown. The authors propose that treating every patient with shortened therapy, regardless of baseline viral load, would lead to significant public cost savings and collateral efficiencies, enabling increased HCV treatment capacity and cure. |
| format | Article |
| id | doaj-art-f558508755cc4fe7ba76356717da85e2 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-f558508755cc4fe7ba76356717da85e22025-02-03T01:31:12ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972015-01-0129312512910.1155/2015/591260Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in CanadaSergio M Borgia0Adenike Rowaiye1William Osler Health System, Brampton Civic Hospital, Brampton, Ontario, CanadaWilliam Osler Health System, Brampton Civic Hospital, Brampton, Ontario, CanadaBACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to predominately single-payer health care systems such as that found in Ontario. In hepatitis C virus (HCV) genotype 1 noncirrhotic patients with a baseline viral load of <6×106 IU/mL, treatment with sofosbuvir-ledipasvir can be shortened to eight weeks without compromising ≥95% efficacy. The number of HCV-infected patients in Ontario eligible for shortened therapy, and the associated cost savings, are unknown. The authors propose that treating every patient with shortened therapy, regardless of baseline viral load, would lead to significant public cost savings and collateral efficiencies, enabling increased HCV treatment capacity and cure.http://dx.doi.org/10.1155/2015/591260 |
| spellingShingle | Sergio M Borgia Adenike Rowaiye Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada Canadian Journal of Gastroenterology and Hepatology |
| title | Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada |
| title_full | Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada |
| title_fullStr | Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada |
| title_full_unstemmed | Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada |
| title_short | Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada |
| title_sort | increased eligibility for treatment of chronic hepatitis c infection with shortened duration of therapy implications for access to care and elimination strategies in canada |
| url | http://dx.doi.org/10.1155/2015/591260 |
| work_keys_str_mv | AT sergiomborgia increasedeligibilityfortreatmentofchronichepatitiscinfectionwithshorteneddurationoftherapyimplicationsforaccesstocareandeliminationstrategiesincanada AT adenikerowaiye increasedeligibilityfortreatmentofchronichepatitiscinfectionwithshorteneddurationoftherapyimplicationsforaccesstocareandeliminationstrategiesincanada |